慢性肾脏病患者的糖尿病管理
Management of diabetes mellitus in patients with chronic kidney disease.
作者信息
Hahr Allison J, Molitch Mark E
机构信息
Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, 60611 Chicago, Illinois USA.
出版信息
Clin Diabetes Endocrinol. 2015 Jun 4;1:2. doi: 10.1186/s40842-015-0001-9. eCollection 2015.
Abstract
Glycemic control is essential to delay or prevent the onset of diabetic kidney disease. There are a number of glucose-lowering medications available but only a fraction of them can be used safely in chronic kidney disease and many of them need an adjustment in dosing. The ideal target hemoglobin A1c is approximately 7 % but this target is adjusted based on the needs of the patient. Diabetes control should be optimized for each individual patient, with measures to reduce diabetes-related complications and minimize adverse events. Overall care of diabetes necessitates attention to multiple aspects, including reducing the risk of cardiovascular disease, and often, multidisciplinary care is needed.
摘要
血糖控制对于延缓或预防糖尿病肾病的发生至关重要。有多种降糖药物可供使用，但其中只有一小部分能在慢性肾病患者中安全使用，而且许多药物需要调整剂量。理想的糖化血红蛋白A1c目标约为7%，但该目标会根据患者的需求进行调整。应针对每位患者优化糖尿病控制，采取措施减少糖尿病相关并发症并将不良事件降至最低。糖尿病的整体护理需要关注多个方面，包括降低心血管疾病风险，而且通常需要多学科护理。
相似文献
1
Management of diabetes mellitus in patients with chronic kidney disease.
Clin Diabetes Endocrinol. 2015 Jun 4;1:2. doi: 10.1186/s40842-015-0001-9. eCollection 2015.
3
Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
J Manag Care Pharm. 2010 May;16(4):264-75. doi: 10.18553/jmcp.2010.16.4.264.
4
Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis.
JBI Database System Rev Implement Rep. 2016 Jul;14(7):169-207. doi: 10.11124/JBISRIR-2016-003011.
5
The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review.
JBI Libr Syst Rev. 2012;10(42 Suppl):1-10. doi: 10.11124/jbisrir-2012-170.
6
Glycemic Control in Patients with Diabetic Kidney Disease; Time to Recognize Perils of Iatrogenic Hypoglycemia?Moving away from Intensive Glycemic Control.
J Assoc Physicians India. 2018 Sep;66(9):70-75.
7
Glycemic control and its associated factors among adult diabetic patients in Southern Ethiopia: a cross-sectional study.
Afr Health Sci. 2024 Mar;24(1):187-197. doi: 10.4314/ahs.v24i1.23.
8
Hypoglycemia in People with Type 2 Diabetes and CKD.
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):844-853. doi: 10.2215/CJN.11650918. Epub 2019 Apr 17.
9
[Therapy of diabetes mellitus in patients with chronic kidney disease].
Dtsch Med Wochenschr. 2019 Aug;144(15):1044-1050. doi: 10.1055/a-0654-0783. Epub 2019 Jul 26.
10
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1693-1702. doi: 10.2215/CJN.06200518. Epub 2018 Oct 25.
引用本文的文献
1
Glycemic Control in Patients with Diabetes on Peritoneal Dialysis: From Glucose Sparing Approach to Glucose Monitoring.
Life (Basel). 2025 May 17;15(5):798. doi: 10.3390/life15050798.
2
Comprehending the Role of Metabolic and Hemodynamic Factors Alongside Different Signaling Pathways in the Pathogenesis of Diabetic Nephropathy.
Int J Mol Sci. 2025 Apr 3;26(7):3330. doi: 10.3390/ijms26073330.
3
A validation study of the Intentional Nonadherence Scale among people with type 2 diabetes in the United Kingdom.
Diabet Med. 2025 Jun;42(6):e70040. doi: 10.1111/dme.70040. Epub 2025 Apr 5.
4
Optimizing chronic kidney disease management: The potential of a multi-strain probiotic formulation.
World J Nephrol. 2025 Mar 25;14(1):101515. doi: 10.5527/wjn.v14.i1.101515.
5
Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trials.
Diabetes Obes Metab. 2025 Apr;27(4):2259-2270. doi: 10.1111/dom.16231. Epub 2025 Feb 10.
6
Prescription pattern, glycemic control status, and predictors of poor glycemic control among diabetic patients with comorbid chronic kidney disease in Ethiopia: a facility-based cross-sectional study.
BMC Endocr Disord. 2025 Feb 3;25(1):28. doi: 10.1186/s12902-025-01853-z.
7
In silico design and computational screening of berberine derivatives for potential antidiabetic activity through allosteric activation of the AMPK pathway.
In Silico Pharmacol. 2025 Jan 7;13(1):12. doi: 10.1007/s40203-024-00295-0. eCollection 2025.
8
A retrospective multi-site examination of chronic kidney disease using longitudinal laboratory results and metadata to identify clinical and financial risk.
BMC Nephrol. 2024 Dec 6;25(1):447. doi: 10.1186/s12882-024-03869-4.
9
Attitudes and practices related to hypoglycemia unawareness in patients with type 1 and type 2 diabetes.
J Med Life. 2024 Aug;17(8):806-811. doi: 10.25122/jml-2024-0005.
10
Prediction of People With Type 2 Diabetes Not Achieving HbA1c Target After Initiation of Fast-Acting Insulin Therapy: Using Machine Learning Framework on Clinical Trial Data.
J Diabetes Sci Technol. 2024 Sep 20:19322968241280096. doi: 10.1177/19322968241280096.
本文引用的文献
1
(9) Microvascular complications and foot care.
Diabetes Care. 2015 Jan;38 Suppl:S58-66. doi: 10.2337/dc15-S012.
2
(8) Cardiovascular disease and risk management.
Diabetes Care. 2015 Jan;38 Suppl:S49-57. doi: 10.2337/dc15-S011.
3
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
JAMA. 2014;312(24):2668-75. doi: 10.1001/jama.2014.15298.
4
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
Diabetologia. 2015 Mar;58(3):493-504. doi: 10.1007/s00125-014-3456-9. Epub 2014 Dec 7.
5
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
Diabet Med. 2015 Mar;32(3):305-13. doi: 10.1111/dme.12627. Epub 2014 Dec 3.
6
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.
Diabetes Ther. 2014 Dec;5(2):355-66. doi: 10.1007/s13300-014-0089-4. Epub 2014 Nov 26.
7
Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study.
Diabetes Care. 2014 Aug;37(8):2291-5. doi: 10.2337/dc14-0464. Epub 2014 May 30.
8
Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.
Diabetes Care. 2014 Aug;37(8):2218-24. doi: 10.2337/dc13-3023. Epub 2014 May 19.
9
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.
Kidney Int. 2015 Jan;87(1):20-30. doi: 10.1038/ki.2014.128. Epub 2014 Apr 30.
10
Association between glycemia and mortality in diabetic individuals on renal replacement therapy in the U.K.
Diabetes Care. 2014;37(5):1304-11. doi: 10.2337/dc13-0553. Epub 2014 Feb 26.
Zotero 插件